| Autor: |
Udeh R; Hunter Medical Research Institute Building, School of Medicine & Public Health, The University of Newcastle, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW 2305, Australia., Advani S; Terasaki Institute of Biomedical Innovation, Los Angeles, CA 90024, USA., de Guadiana Romualdo LG; Hospital Universitario Santa Lucía, Calle Minarete s/n, 30202 Cartagena Murcia, Spain., Dolja-Gore X; Hunter Medical Research Institute Building, School of Medicine & Public Health, The University of Newcastle, Lot 1, Kookaburra Circuit, New Lambton Heights, NSW 2305, Australia. |
| Abstrakt: |
COVID-19 has been shown to present with varied clinical course, necessitating a need for more specific diagnostic tools that could identify severe cases and predict outcomes during COVID-19 infection. Recent evidence has shown an expanded potential role for calprotectin, both as a diagnostic tool and also as a tool in stratifying COVID-19 patients in terms of severity. Therefore, this systematic review and meta-analysis aims to evaluate the levels of calprotectin in severe and non-severe COVID-19 and also identify the implication of raised calprotectin levels. MEDLINE, EMBASE, The Cochrane Library, Web of science and MedRxiv were searched. Meta-analysis was done to compare the serum/fecal levels of calprotectin between severe and non-severe COVID-19 infections. A total of ten studies included in the review (eight had quantitative data while two were qualitative). A pooled analysis of the eight studies from 613 patients who were RT-PCR positive for COVID-19 (average age = 55 years; 52% males) showed an overall estimate as 1.34 (95%CI: 0.77, 1.91). In conclusion, calprotectin levels have been demonstrated to be significantly elevated in COVID-19 patients who develop the severe form of the disease, and it also has prognostic importance. |
